publication venue for
- A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. 2023
- Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. 2023
- Characteristics and Clinical Outcomes of Patients with ALK-positive Anaplastic Large Cell Lymphoma: Report from the Prospective International T-Cell Lymphoma Project. 2022
- Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.. 38. 2020
- High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?. 34. 2015
- Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.. 29. 2011
- Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.. 28. 2010
- Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation.. 6. 1988
- Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.. 36. 2017
- Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.. 35. 2016
- Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. 2019
- Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. 2017
- Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 2009
- Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma. 2023
- Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. 2022
- Langerhans cell histiocytosis: Version 2021. 2021
- CAR T-cell therapy: Full speed ahead. 2019
- Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. 2018